More News

Clarifi Imaging System for Microvascular Assessment Receives CE Mark An Important Milestone for Modulim

The CE Mark certification allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

The Ultimate End of Life Planning Checklist

With Pillar, you can get ahead of that by proactively planning. Take things one day at a time so you can be less stressed in the future and focus more on the real things that matter – the person you love.

Francis Medical Launches with $18M Series A Funding for Promising Cancer Ablation Technology Using Water Vapor

December 13, 2018

Francis Medical, Inc., is a Minneapolis-based, privately held medical device company developing an innovative and proprietary vapor ablation therapy to treat a variety of endourology cancers, beginning with Prostate Cancer (PCa). Today the company announced the completion of a $18.0 million round of Series A financing. Arboretum Ventures led the Series A with co-investments from H2Oey Ventures, an affiliate of Solas BioVentures Fund, Tonkawa and Boston Scientific. The company plans to use this capital to initiate further development.

Early feasibility clinical trials in the Dominican Republic, Paraguay and Panama led to the initial $18M in Series A funding. “This investment will support additional international clinical work, followed by a US IDE pilot study in late 2019,” said Michael Kujak, president and chief executive officer, Francis Medical. “Our goal is to move quickly to expand the potential of cancer ablation by water vapor as a vital, non-invasive treatment for prostate cancer as-well-as for kidney and bladder cancers.”

Francis Medical reported the announcement of Michael Kujak as CEO will expedite the formation of Francis Medical and the upcoming product development and clinical work. Kujak has broad global healthcare experience, having spent 30 years in growing leadership positions within medtech. His recent past successes include developing and commercializing innovative medical procedures to treat benign prostate hyperplasia (BPH) at American Medical Systems and NxThera.

Michael Hoey, founder of Francis Medical, and its chief technology officer, is a successful serial inventor and entrepreneur. His most recent success being NxThera which was purchased by Boston Scientific for $306M upfront plus up to $100M additional maximum milestones. Hoey pioneered the use of thermal water vapor to ablate tissue, a minimally-invasive treatment that delivers targeted, controlled doses of stored thermal energy in the form of water vapor directly to the tissue. “Based on the success of initial clinical trials, we are confident that cancer ablation by water vapor will be an effective, next-generation treatment for prostate cancer without the unwanted side effects of urinary incontinence and erectile dysfunction which are associated with radical prostatectomies,” said Hoey. “We foresee this technology as a true minimally invasive breakthrough that will improve quality of life and expand the cancer treatment options available today for patients suffering from prostate, bladder and kidney cancers.”

Latest Posts

TRIMEDX Acquires Centurion Service Group a Full-Service Surplus Medical Equipment Management Company

TRIMEDX’s acquisition of Centurion Service Group will enhance TRIMEDX’s clinical asset management and informatics solutions.

Clarifi Imaging System for Microvascular Assessment Receives CE Mark An Important Milestone for Modulim

The CE Mark certification allows Modulim to now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Muvr Labs Is Acquired by Exactech

Orthopaedic surgeon Alexander Sah, MD, in Fremont, Calif. has seen the positive impact of Muvr technology on his practice. “Patients are attracted to the technology because they know our team is monitoring their progress; remarkably, this has caused my patients to take more ownership of their recovery,” he said.

Don't Miss

New England Biolabs Announces Further Expansion of Their RNA Depletion Product Portfolio with the Launch of the NEBNext Custom RNA Depletion Design Tool and NEBNext RNA Depletion Core Reagent...

Together, these enable a fully customizable workflow for improved removal of specific RNAs, including abundant RNAs such as ribosomal RNA

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

Genetron Health Provides Update on HCCscreen™ for Liver Cancer Early Screening in China

Establishes joint venture with Wuxi municipal government; Expects the commercialization and revenues of HCCscreen to accelerate in China.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials.